Abbreviations: WT, wild type; APC, activated protein C; PS, protein S; EPCR, endothelial protein C receptor; PAR, protease activated receptor; APTT, activated partial thromboplastin time; PT, prothrombin time; TBS, tris-buffered saline; BSA, bovine serum albumin; SDS-PAGE, sodium dodecyl sulfate polyacrylamid gel electrophoresis.
Protein C is a vitamin K-dependent protein that circulates in plasma as a zymogen to a serine protease with anticoagulant properties [1] [2] [3] [4] . In response to thrombin generation, protein C is activated on the endothelial surface by the thrombin-thrombomodulin complex [4] . Activated protein C (APC) together with its cofactor protein S (PS) effectively down-regulates blood coagulation by cleaving and inhibiting the two cofactors activated factor V (FVa) and activated factor VIII (FVIIIa) [5, 6] . Several cleavage sites have been identified in both FVa and FVIIIa, of which the cleavages at Arg306 and Arg506 in FVa have been studied in detail [7] [8] [9] [10] [11] [12] .
The physiological importance of the anticoagulant properties of APC is best illustrated by the increased risk of venous thrombosis in individuals with genetic defects affecting the protein C system [1, 13, 14] . In addition to its anticoagulant properties, APC has been shown to possess anti-inflammatory functions, which appear to depend on the presence of endothelial protein C receptor (EPCR) [15] . EPCR is suggested to direct the proteolytic activity of APC towards the protease activated receptor 1 (PAR1) rather than to FVa and FVIIIa [16] . APC has been shown to be efficient in the treatment of septic shock, the beneficial effects possibly being due to both the anticoagulant and anti-inflammatory properties of APC [15, 17] .
The anticoagulant properties of APC make it an interesting therapeutic candidate for prevention and treatment of venous and arterial thrombosis. There are several reports on record investigating the effect of APC in different animal models [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . We have previously described powerful antithrombotic effects of bovine APC (bAPC) in combination with bovine PS (bPS) in both rabbit and rat models of deep arterial injury [18] [19] [20] 32] .
We have recently created several recombinant human protein C variants with enhanced anticoagulant activity and the aim of the present investigation was to elucidate their antithrombotic potential in the arterial thrombosis model in the rat. In one of the variants, QGNSEDY-hAPC (H10Q/S11G/S12N/D23S/Q32E/N33D/H44Y), the membrane-binding properties of APC were altered by mutagenesis of the γ-carboxyglutamic acid (Gla)-rich domain. This variant proved to be highly effective as an anticoagulant in human plasma and QGNSEDY-hAPC alone was found to be more potent than WT hAPC together with hPS in a FVa degradation assay [33] . In another recombinant hAPC variant (hAPC:B148), loop 148 in the serine protease domain was exchanged for the corresponding bovine loop, which resulted in a hAPC variant with modestly enhanced catalytic and anticoagulant activity [34] . By combining the mutations in QGNSEDY-hAPC and hAPC:B148 we have now created a new hAPC variant (QGNSEDY-hAPC:B148), which is more effective as an anticoagulant than either of the two original variants.
In this study, we have investigated the antithrombotic, antihaemostatic, and anticoagulant effects of recombinant WT hAPC as well as the two recombinant hAPC variants QGNSEDYhAPC and QGNSEDY-hAPC:B148. Despite demonstrating strong anticoagulant effects in vitro using rat plasma, the two hAPC variants failed to demonstrate antithrombotic effects in the arterial thrombosis model in the rat.
MATERIALS AND METHODS

Recombinant protein C variants
Full length cDNAs for the QGNSEDY-hPC and hPC:B148 introduced in the HindIII and XbaI sites in the pRC/CMV vector were created with recombinant DNA-techniques, as previously described [33] [34] [35] [36] . The mutations in the QGNSEDY variant was H10Q/S11G/S12N/D23S/Q32E/N33D/H44Y, where the first letter preceding the amino-acid number is the one-letter abbreviation for the wild-type amino acid, and the letter after the number refers to the amino acid residue introduced by the mutagenesis [33] .
The amino-acid numbers refer to the positions in the mature protein, i.e. after removal of the signal sequence and propeptide. In the hPC: B148 mutant, the 148 loop in human protein C, GWGYHSSREKEAKRN (the underlined amino acids correspond to positions 303-310 in the linear sequence, and to 144-149b according to the chymotrypsinogen numbering), was replaced by the four residues shorter corresponding loop in bAPC (GWGYRDETKRN) [34] .
The cDNA for the new mutant used in this study QGNSEDY-hPC:B148 was constructed by combining the appropriate fragments of the cDNAs for QGNSEDY and hPC: B148. Thus, the 360 bp HindII-SalI fragment of QGNSEDY cDNA was ligated together with the 1140 bp SalI-Xba I fragment of hPC:B148 cDNA into the pRC/CMV vector.
The cDNAs corresponding to WT hPC and the two variants QGNSEDY-hPC and QGNSEDY-hPC:B148, inserted in the eukaryotic expression vector pRc/CMV, were used to transfect the human kidney cell line 293. High-expressing colonies were selected for largescale culture and subsequent purification, as previously described [35] . The recombinant protein C variants were activated by thrombin, and then passed through a chromatography column of SP-Sephadex to remove thrombin essentially, as earlier described [36] .
In vitro coagulation analyses
Citrated rat plasma was acquired from male Sprague-Dawley albino rats and used for in vitro characterization of the anticoagulant activities of the various hAPC variants. Increasing concentrations of the three hAPC variants were added in clotting assays using either the APTT reagent Platelin LS (Biomerieux, Marcy l'Etoile, France) or the PT reagent Simplastin Excel (Biomerieux). Each experiment was performed three times in duplicates and the mean values were used for presentation.
In the APTT system, 50µl plasma was mixed with 50µl Platelin LS (diluted 1:2) and incubated for 180 seconds at temperature 37°C before initiation of coagulation by 50µl of Bovine Serum Albumin (BSA). The reason for diluting the reagents was that the clotting times were very short when undiluted reagents were used. The clotting times were measured using an Amelung KC 10 instrument (Amelung Heinrich, Lemgo, Germany).
Thrombosis Model
Fifteen Sprague-Dawley male albino rats with a mean body weight 291 grams (range 256-334 grams) were used in the pilot study. Fifty Sprague-Dawley male albino rats were used in the full-scale experiment with a mean body weight of 285 grams (range 246-334 grams). The 
Experimental Protocol
In the pilot study, 15 rats were divided into 5 groups and treated either with increasing doses of QGNSEDY-hAPC:B148 (0.1, 0.2, 0.4 or 0.8 mg/kg) or vehicle only (n=3 in each group).
In the full-scale experiment, 50 rats were divided into 4 groups that were treated either with recombinant WT hAPC 0.8 mg/kg (n=10), QGNSEDY-hAPC 0.8 mg/kg (n=10), QGNSEDYhAPC:B148 0.8 mg/kg (n=10) or vehicle only (n=20).
All experiments were performed in a blind random fashion. The randomized substances were stored in 1.5 ml coded Eppendorf plastic tubes (Sarstedt, Numbrecht, Germany) at -78°C and thawed to room temperature immediately before use. The substances were delivered as intravenous weight-adjusted bolus injections after completing the vascular injury, one minute before reperfusion. The infusion volume was 0.21 ml per 100-gram animal weight in all groups. The vehicle was 20 mM Tris-HCl, 0.15 M NaCl, pH 7.5, containing 2 mg/ml BSA.
Ex vivo coagulation analyses
Blood samples (0.9 ml) for coagulation analyses were drawn from the femoral vein a) 1 minute before injection of the randomized substance (baseline data), b) 2 minutes after reperfusion (i.e., 3 minutes after injection of the randomized substance) and c) 30 minutes after reperfusion (i.e., 31 minutes after injection of randomized substance and 1 minute before the patency test). Before each blood sample was collected, 0.5 ml of blood was drawn into a separate syringe and wasted. After every 0.9-ml sample of blood was collected, 0.5 ml of saline was injected with another syringe to clear the catheter from blood.
The blood samples were collected with a 2-ml plastic syringe (Plastipak; Becton Dickinson AB, Hägersten, Stockholm, Sweden) prefilled with 0.1 ml of 3.8% 0.13 M sodium citrate. The samples were immediately transferred to 1.5-ml Eppendorf plastic tubes that were centrifuged at 14 000 rpm for 3 minutes (Mikro 12/24; Hettich Zentrifugen, Tuttlingen, Germany). The plasma was separated with a pipette and put in two Eppendorf tubes with 300 µl of plasma in each. The tubes were put in a box containing pellets of carbon acid ice. After completion of the daily experiments, the plasma samples were transferred to a freezer maintaining a temperature of -78°C. 
Expression and purification of recombinant protein C variants
The expression levels of the three recombinant proteins in 293-cells were between 3-5 mg/L.
The proteins were collected under serum-free conditions and purified by anion exchange chromatography with overall recoveries of 35 to 40%. On 10% SDS-PAGE the mutant and WT proteins migrated to similar positions corresponding to a molecular weight (MW) of approximately 60 kDa (Fig. 1) . The light and heavy chains of the proteins were separated after reduction of disulfide bonds. In the reduced forms, the α and β (but no γ)-isoforms of the heavy chain as well as the light chain were seen. All three reduced protein C variants contained a smaller amount of the single-chain form that disappeared after activation by thrombin, while the heavy chain isoforms shifted to slightly lower MW-positions, consistent with full activation (Fig. 1) .
In vitro anticoagulant effect
In the in vitro clotting experiments, analyses with the APTT reagent Platelin LS (intrinsic pathway) showed that WT hAPC alone only slightly prolonged the clotting time in rat plasma.
In contrast, the two mutants clearly prolonged the clotting time in a dose dependent manner with approximately tripled and quadrupled clotting times, respectively, at the highest concentrations ( Fig. 2A) . Analyses with the tissue factor pathway reagent Simplastin Excel showed similar clotting time patterns in rat plasma with pronounced anticoagulant effect achieved by the mutants and only a minor effect by WT hAPC (Fig. 2B) .
Antithrombotic effect
In the pilot study, 2/3 vessels were patent in both groups given the highest doses (0.4 and 0.8 mg/kg) of QGNSEDY-hAPC:B148, 0/3 vessels in each of the groups receiving 0.1 and 0.2 mg/kg, and 1/3 vessels in the control group (Fig. 3A) . In the full scale experiment, the administration of WT hAPC or mutants did not produce any antithrombotic effect when compared to the control group, the patency rates being 3/10 vessels in the groups given WT hAPC and QGNSEDY-hAPC:B148 and 5/10 in the QGNSEDY-hAPC group, compared to 6/20 vessels in the control group (p= 1.00 and p= 0.42 respectively) (Fig. 4A) .
Arteriotomy bleeding
In the pilot study, the arteriotomy bleeding seemed to be similar in all groups, but the groups were too small to make reliable statistical comparisons (data not shown). In the full-scale experiment, administration of different forms of hAPC did not increase the arteriotomy bleeding compared to controls; the median cumulative arteriotomy bleeding during 31 minutes of observation was 1.1 grams in the control group, which was not significantly different from the other groups (Fig. 4B) .
Ex vivo coagulation analyses
In the pilot study, the clotting time increased in a dose dependent manner with QGNSEDYhAPC:B148 (Fig. 3B) , and the clotting times in the highest dose were similar to those in the full scale experiment with the same mutant as described below. In the full-scale study, administration of WT hAPC only slightly increased the APTT in rat plasma. The mutant QGNSEDY-hAPC doubled and QGNSEDY-hAPC:B148 approximately tripled the clotting time, measured at three minutes after injection of substance (Fig. 4C) . The clotting times measured by Simplastin Excel were increased by approximately 1.5 and 2 times, respectively, DISCUSSION Arterial and venous thrombosis is a major medical problem motivating the search for improved antithrombotic agents. The specific anticoagulant activity of APC makes it an attractive candidate as a therapeutic compound and it has already proven its effect in association with severe septic shock [4, 17] . In models of arterial thrombosis in the rat, we have previously demonstrated bovine APC to be efficient as an antithrombotic agent when coadministered with bovine protein S [18] [19] [20] 32] . The present in vitro clotting experiments in rat plasma performed with either APTT or PT reagents, showed distinct dose dependent anticoagulant effect, especially with the mutant QGNSEDY-hAPC:B148 with four-fold prolongation at the highest concentration in the APTT system in contrast to WT-hAPC that only slightly prolonged the clotting time. The powerful anticoagulant response of the mutants generated the hypothesis that the mutants could be antithrombotic without co-administration of human protein S (hPS) in our experimental model. In the pilot study with increasing doses of the mutant QGNSEDY-hAPC:B148 there was antithrombotic effect in 4 out of 6 vessels in the two highest doses and the ex vivo anticoagulant response was similarly dose dependent as in the in vitro experiments. This combination of results led us to perform the larger study in which we observed the expected prolongation of the clotting time with the mutants but no significant antithrombotic effect compared to the control group, even though the pilot study had indicated that this could be possible.
The poor antithrombotic effects of hAPC now observed differ from observations in other studies, which report antithrombotic effects in arterial models of thrombosis in rats after intravenous injection of plasma purified hAPC. Smirnov et al 1990 demonstrated that injection of low doses of hAPC (15 or 30 µg/kg) prolonged the time to complete occlusion of rat abdominal aorta that was made thrombogenic by electrical current [27] . Araki et al 1991 showed that intravenous injection of hAPC (0.9 or 3.0 mg/kg) significantly decreased the number of thrombotic occlusions and the total time the vessels were occluded in rat mesenteric artery after compression injury [25] . Yamashita et al 1994 described a rat model with repeated laser irradiation of mesenteric microvessels where intravenous injection of hAPC (0.40 mg/kg) significantly increased the number of laser irradiations necessary to achieve total occlusion of arterioles [28] . Hashimoto and colleagues showed decreased thrombus size after injection of hAPC (1.62 mg/kg) in rats with laser-induced thrombosis in mesenteric arterioles [29, 30] . The discrepancy between our and these previous findings may in part be explained by differences in the type of vascular injury used. In contrast to the previous studies [25, [27] [28] [29] [30] , the vascular trauma in our model was designed to mimic conditions that may be encountered in clinical settings, such as avulsion trauma or exposure of deep vascular layers in diseased vessels after atherosclerotic plaque rupture, i.e. a crude vascular trauma that produces occlusive thrombus formation and an injury that is prone to be relatively resistant to therapeutic intervention. Also, it is notable that the above-mentioned studies contained small treatment groups and were not performed in a blind randomized manner.
We have created several recombinant hAPC variants that express enhanced anticoagulant and catalytic effect in vitro as compared to WT hAPC and the aim of the present investigation was to test their efficacy as antithrombotic agents in vivo. The two hAPC variants we now used, QGNSEDY-hAPC and QGNSEDY-hAPC:B148 share the mutated Gla-domain, which provides the molecules with enhanced affinity for negatively charged phospholipids membranes. In a human plasma system, the QGNSEDY-hAPC variant has been shown to be highly efficient as anticoagulant [33] and in the in vitro clotting assay using rat plasma, this variant was much more potent as anticoagulant than WT hAPC.
The QGNSEDY-hAPC:B148 variant, which combines the Gla-domain mutation with a loop 148 change that we previously found to be associated with enhanced catalytic and anticoagulant activity [34] , was even more active than the QGNSEDY-hAPC variant in the in vitro clotting assays.
Despite being efficient as anticoagulants in vitro and ex vivo, none of the hAPC variants demonstrated antithrombotic effects in the rat model. It remains to be investigated whether the addition of human protein S make the hAPC variants more antithrombotic. With respect to the poor antithrombotic effect of the human APC variants, it should be remembered that the antithrombotic effects of the protein C system appear to be particularly important to inhibit thrombus formation on the venous side, as individuals carrying genetic defects affecting the system mainly suffer from venous and not arterial thrombosis [13, 14] . Thus, the APC variants we now investigated may be efficient in less thrombogenic settings and in models of venous thrombosis. As human APC is poorly active as an anticoagulant in rat plasma, it is also possible that these APC variants would be efficient as antithrombotic agents in humans.
In summary, we have investigated WT hAPC and two hAPC variants expressing increased anticoagulant activity in a rat arterial thrombosis model. None of the tested variants produced antithrombotic effect even though the two variant hAPCs gave distinct anticoagulant responses in rat plasma. The locations of the α and β iso-forms of the HC are indicated. 
